When hypereosinophilia occurs during dupilumab therapy: evidence-based strategies for clinical management in respiratory indications
Blood eosinophil count itself should not preclude dupilumab prescription, neither lead to dupilumab discontinuation, especially in the presence of ascertained drug efficacy and in the absence of signs suggesting a eosinophils-related complication. However, an extensive diagnostic work-up and regular follow-up monitoring is indicated, especially in patients with increased baseline eosinophils and coexisting nasal polyps and asthma.
Authors
- Antonella Loperfido (ORCID: https://orcid.org/0000-0002-7174-8126)
- Andrea Portacci (ORCID: https://orcid.org/0000-0002-6127-2486)
- Marco Caminati (ORCID: https://orcid.org/0000-0001-7383-1487)
- Claudio Montuori (ORCID: https://orcid.org/0000-0003-2070-0314)
- Marco Zurlo (ORCID: https://orcid.org/0000-0003-4064-070X)
- Francesca Cefaloni (ORCID: https://orcid.org/0009-0004-6929-0912)
- L. D’Auria (ORCID: https://orcid.org/0009-0007-7101-1080)
- Eugenio De Corso (ORCID: https://orcid.org/0000-0001-5761-7018)
- Giovanna Elisiana Carpagnano (ORCID: https://orcid.org/0000-0001-7931-4704)
- Michele Schiappoli (ORCID: https://orcid.org/0000-0002-4718-5984)
- Matteo Maule
Institutions
- Università Cattolica del Sacro Cuore (IT)
- University of Verona (IT)
- Agostino Gemelli University Polyclinic (IT)
- University Hospital Foundation (CA)
- Nini Hospital (LB)
- University of the Sacred Heart (JP)
- University of Bari Aldo Moro (IT)
Publication Details
- Journal
- Expert Review of Respiratory Medicine
- Published
- 2025-12-14
- DOI
- https://doi.org/10.1080/17476348.2025.2604322
- Citations
- 2
- Primary Topic
- Eosinophilic Disorders and Syndromes
- Type
- article
- Field-Weighted Citation Impact
- 3.34